<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Yin G</submitter><funding>National Natural Science Foundation of China</funding><funding>the project of the Beijing Municipal Science and Technology Commission</funding><pagination>2196</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9607073</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>14(10)</volume><pubmed_abstract>To develop novel radiolabeled amino acid tumor imaging agents, 4-methoxy-&lt;sub>L&lt;/sub>-phenylalanine dithiocarbamate (MOPADTC) was synthesized successfully, and two kinds of &lt;sup>99m&lt;/sup>Tc-labeled complexes ([&lt;sup>99m&lt;/sup>Tc]TcN-MOPADTC and [&lt;sup>99m&lt;/sup>Tc]TcO-MOPADTC) with high radiochemical purities (RCP &amp;gt; 95%) were obtained. The in vitro stability and partition coefficient were determined, and the results show that both of these complexes have good in vitro stability; [&lt;sup>99m&lt;/sup>Tc]TcO-MOPADTC is hydrophilic, while [&lt;sup>99m&lt;/sup>Tc]TcN-MOPADTC is slightly lipophilic. The biodistribution of [&lt;sup>99m&lt;/sup>Tc]TcN-MOPADTC and [&lt;sup>99m&lt;/sup>Tc]TcO-MOPADTC in mice bearing S180 tumors shows that the tumor uptake and tumor/muscle ratio of [&lt;sup>99m&lt;/sup>Tc]TcO-MOPADTC were higher than the tumor uptake and tumor/muscle ratio of [&lt;sup>99m&lt;/sup>Tc]TcN-MOPADTC. In addition, the tumor retention of [&lt;sup>99m&lt;/sup>Tc]TcO-MOPADTC is better than the tumor retention of [&lt;sup>99m&lt;/sup>Tc]TcN-MOPADTC. A competitive inhibition assay was performed, and the results indicate that [&lt;sup>99m&lt;/sup>Tc]TcO-MOPADTC may enter cells primarily via the &lt;sub>L&lt;/sub>-alanine/&lt;sub>L&lt;/sub>-serine/&lt;sub>L&lt;/sub>-cysteine (ASC) system. Single-photon emission computed tomography (SPECT) imaging of [&lt;sup>99m&lt;/sup>Tc]TcO-MOPADTC shows obvious accumulation in tumor sites, suggesting that [&lt;sup>99m&lt;/sup>Tc]TcO-MOPADTC is a novel potential tumor-imaging agent.</pubmed_abstract><journal>Pharmaceutics</journal><pubmed_title>Radiolabeling and Biological Evaluation of Novel &lt;sup>99m&lt;/sup>Tc-Nitrido and &lt;sup>99m&lt;/sup>Tc-Oxo Complexes with 4-Methoxy-&lt;sub>L&lt;/sub>-Phenylalanine Dithiocarbamate for Tumor Imaging.</pubmed_title><pmcid>PMC9607073</pmcid><funding_grant_id>Z181100002218033</funding_grant_id><funding_grant_id>22076013</funding_grant_id><funding_grant_id>21771023</funding_grant_id><pubmed_authors>Jiang Y</pubmed_authors><pubmed_authors>Yin G</pubmed_authors><pubmed_authors>Zhang J</pubmed_authors><pubmed_authors>Ruan Q</pubmed_authors></additional><is_claimable>false</is_claimable><name>Radiolabeling and Biological Evaluation of Novel &lt;sup>99m&lt;/sup>Tc-Nitrido and &lt;sup>99m&lt;/sup>Tc-Oxo Complexes with 4-Methoxy-&lt;sub>L&lt;/sub>-Phenylalanine Dithiocarbamate for Tumor Imaging.</name><description>To develop novel radiolabeled amino acid tumor imaging agents, 4-methoxy-&lt;sub>L&lt;/sub>-phenylalanine dithiocarbamate (MOPADTC) was synthesized successfully, and two kinds of &lt;sup>99m&lt;/sup>Tc-labeled complexes ([&lt;sup>99m&lt;/sup>Tc]TcN-MOPADTC and [&lt;sup>99m&lt;/sup>Tc]TcO-MOPADTC) with high radiochemical purities (RCP &amp;gt; 95%) were obtained. The in vitro stability and partition coefficient were determined, and the results show that both of these complexes have good in vitro stability; [&lt;sup>99m&lt;/sup>Tc]TcO-MOPADTC is hydrophilic, while [&lt;sup>99m&lt;/sup>Tc]TcN-MOPADTC is slightly lipophilic. The biodistribution of [&lt;sup>99m&lt;/sup>Tc]TcN-MOPADTC and [&lt;sup>99m&lt;/sup>Tc]TcO-MOPADTC in mice bearing S180 tumors shows that the tumor uptake and tumor/muscle ratio of [&lt;sup>99m&lt;/sup>Tc]TcO-MOPADTC were higher than the tumor uptake and tumor/muscle ratio of [&lt;sup>99m&lt;/sup>Tc]TcN-MOPADTC. In addition, the tumor retention of [&lt;sup>99m&lt;/sup>Tc]TcO-MOPADTC is better than the tumor retention of [&lt;sup>99m&lt;/sup>Tc]TcN-MOPADTC. A competitive inhibition assay was performed, and the results indicate that [&lt;sup>99m&lt;/sup>Tc]TcO-MOPADTC may enter cells primarily via the &lt;sub>L&lt;/sub>-alanine/&lt;sub>L&lt;/sub>-serine/&lt;sub>L&lt;/sub>-cysteine (ASC) system. Single-photon emission computed tomography (SPECT) imaging of [&lt;sup>99m&lt;/sup>Tc]TcO-MOPADTC shows obvious accumulation in tumor sites, suggesting that [&lt;sup>99m&lt;/sup>Tc]TcO-MOPADTC is a novel potential tumor-imaging agent.</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Oct</publication><modification>2025-04-18T20:20:25.639Z</modification><creation>2025-04-07T08:14:41.249Z</creation></dates><accession>S-EPMC9607073</accession><cross_references><pubmed>36297631</pubmed><doi>10.3390/pharmaceutics14102196</doi></cross_references></HashMap>